Pfizer

Have we yet seen the end of Covid restrictions? It is tempting to think so. For many people, Covid and the lockdowns have receded into history, replaced by Ukraine and the energy crisis. It would be easy, but foolish, to dismiss Tony Blair’s proposals as the ramblings of a bored ex-PM But perhaps we have parked the whole business in our memories a little too soon. Some are already pushing for restrictions to be re-enacted this winter. The Tony Blair Institute for Global Change has just published a paper, Three Months to Save the NHS, demanding that the government consider re-imposing mask mandates on public transport and other enclosed settings.

Israel has today become the first country in the world to offer a third Covid-19 booster vaccine on a large scale. Prime Minister Naftali Bennett announced that Israel will vaccinate all people over the age of 60 again, with the new Israeli President, Isaac Herzog, and his wife, the first people to receive their third shot on Friday morning. Legitimate concerns led to the decision: the number of new Covid cases in Israel has been rapidly increasing, including among the vaccinated – although to a much lesser degree compared with those who have not been vaccinated. There were 2,143 confirmed cases on Thursday, with 286 hospitalisations. Israeli experts who are

There is a myth in football that you are always most susceptible to letting in a goal after you have just scored one. It’s probably not true but the idea is attractive. At the peak of our achievement we are vulnerable to complacency. Is a similar thing happening with the vaccine programme? The current prevailing narrative is that the declining rates of vaccination are the fault of the under 30s. Government scientists accept that the country is ‘close to maximum take-up’, with many young people still hesitant about vaccination, the Times reported this week. But is that right? There is probably some truth to the less-than-urgent demand amongst this lower-risk

Should the NHS be mixing vaccines for better effect, or at least offering people who have had one dose of the AstraZeneca vaccine the choice of having the Pfizer vaccine for their second shot?  The question arises because that is exactly the regime which has been followed in Germany since the risk of clotting from the AstraZeneca vaccine became evident. When the German authorities made the decision to administer the Pfizer vaccine in place of a second shot of AstraZeneca there was not much evidence as to whether this would be an effective strategy.  But a study from a group of hospitals in Berlin suggests that a shot of AstraZeneca

For residents of six London boroughs, as well as those in Smethwick in the West Midlands, the partial relaxation of lockdown rules this week hasn’t quite gone according to plan. They’ve had a day out in the sun, alright, but not necessarily sitting enjoying food and drinks in a pub garden – more likely they have been standing in a long queue to get ‘surge tested’ for the South African variant of SARS-CoV-2, the virus which causes Covid-19. So how much of a threat is the South African variant? In spite of anecdotal claims from South Africa that the new variant was affecting younger people, there is no evidence that

Pfizer and BioNTech have released some extraordinary findings from a Phase 3 trial involving 46,307 participants, between seven days and six months after a second dose was administered. The vaccine was found to have a 91.3 per cent efficacy rate. These findings line up with the real world data coming out of Israel, which has used the Pfizer vaccine to inoculate its population, and reported several weeks ago that it proved 94 per cent effective in preventing symptomatic illness. But on top of the overall efficacy rate came even better news: Pfizer is reporting that the ‘vaccine was 100 per cent effective in preventing severe disease’ as defined by the

Reports have filtered through this morning about Public Health England’s assessment of the efficacy of the two vaccines so far administered to the public. The results have not yet been published, but the efficacy rates quoted in the Sun suggest that the Pfizer vaccine has proved to be between 79 and 84 per cent effective at stopping symptomatic infection after two doses. After one dose – which is all that most people have had so far – efficacy is reported as 65 per cent. Among the over 80s it is very similar, at 64 per cent. No figures are given for the AstraZeneca vaccine but it is suggested that the efficacy

Today the United Kingdom became the first country in the West to clinically authorise a vaccine protecting against Covid-19, after the medicines regulator, the MHRA, said the Pfizer/BioNTech vaccine was safe to use. The announcement puts Britain ahead of Europe when it comes to rolling out the vaccine, as the EU’s own regulator, the European Medicines Agency (EMA), has not yet approved the vaccine. While Britain will begin administering Pfizer’s vaccine next week, countries like Belgium have announced that they will start their vaccination campaigns in January, subject to EMA approval. When it comes to vaccines, a few weeks of delay can make a big difference, given the economic and